AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 35953729 — intervention group
Group type: COMPARATOR
Intervention: Duloxetine
Number of subjects: 0
Study 33638625 — intervention group
Group type: EXPERIMENTAL
Intervention: Fexofenadine/pseudoephedrine combination tablet (F/P)
Number of subjects: 24
Study 33638625 — intervention group
Group type: COMPARATOR
Intervention: Fexofenadine (F)
Number of subjects: 24
Study 32762736 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychological skills training (PST)
Number of subjects: 95
Study 32762736 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness training (MT)
Number of subjects: 95
Study 32762736 — intervention group
Group type: COMPARATOR
Intervention: Both PST and MT
Number of subjects: 95
Study 35793110 — intervention group
Group type: EXPERIMENTAL
Intervention: H‐FIRE ablation of all lesions identified with biopsy
Number of subjects: 109
Study 33383198 — intervention group
Group type: EXPERIMENTAL
Intervention: Irrigation group (n=21)
Number of subjects: 40
Study 33383198 — intervention group
Group type: COMPARATOR
Intervention: Nonirrigation group (n=19)
Number of subjects: 40
Study 32822600 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitisinone 10 mg daily
Number of subjects: 138
Study 32822600 — intervention group
Group type: COMPARATOR
Intervention: Control (no treatment)
Number of subjects: 138
Study 36114738 — intervention group
Group type: EXPERIMENTAL
Intervention: High-volume resistance training (HVG; 5 sets/exercise)
Number of subjects: 38
Study 36114738 — intervention group
Group type: COMPARATOR
Intervention: Moderate-volume resistance training (MVG; 3 sets/exercise)
Number of subjects: 38
Study 33509270 — intervention group
Group type: EXPERIMENTAL
Intervention: Controlled hypotension with target mean arterial pressure 65 mmHg (MAP 65)
Number of subjects: 40
Study 33509270 — intervention group
Group type: COMPARATOR
Intervention: Controlled hypotension with target mean arterial pressure 75 mmHg (MAP 75)
Number of subjects: 40
Study 33509270 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (MAP 65 and MAP 75)
Number of subjects: 40
Study 32795925 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg/d antofloxacin (AT)
Number of subjects: 24
Study 32795925 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 mg/d antofloxacin (AT)
Number of subjects: 24
Study 32795925 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 mg/d moxifloxacin
Number of subjects: 24
Study 32795925 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 33275787 — intervention group
Group type: EXPERIMENTAL
Intervention: Tele‐BA (behavioral activation tele-delivered by bachelor's‐level lay counselors)
Number of subjects: 277
Study 33275787 — intervention group
Group type: EXPERIMENTAL
Intervention: Tele‐PST (problem-solving therapy tele-delivered by licensed clinicians)
Number of subjects: 277
Study 33275787 — intervention group
Group type: COMPARATOR
Intervention: Telephone support calls (attention control)
Number of subjects: 277
Study 34526104 — intervention group
Group type: EXPERIMENTAL
Intervention: Kabasura Kudineer (KSK) 60 mL twice daily for 7 days
Number of subjects: 0
Study 34526104 — intervention group
Group type: COMPARATOR
Intervention: Vitamin C 60,000 IU daily and zinc 100 mg daily for 7 days (Control)
Number of subjects: 0
Study 33599086 — intervention group
Group type: EXPERIMENTAL
Intervention: Warm humidified CO2 (WHCO2) during cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC)
Number of subjects: 10
Study 33599086 — intervention group
Group type: COMPARATOR
Intervention: Standard procedure (non-WHCO2) during cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC)
Number of subjects: 10
Study 33143704 — intervention group
Group type: EXPERIMENTAL
Intervention: Short regimen (9-11 months)
Number of subjects: 0
Study 33143704 — intervention group
Group type: COMPARATOR
Intervention: Long regimen (20+ months)
Number of subjects: 0
Study 34403493 — intervention group
Group type: EXPERIMENTAL
Intervention: Larger tracheal tubes (7.5-mm for men, 7.0-mm for women)
Number of subjects: 172
Study 34403493 — intervention group
Group type: COMPARATOR
Intervention: Smaller tracheal tubes (6.5-mm for men, 6.0-mm for women)
Number of subjects: 172
Study 32986087 — intervention group
Group type: EXPERIMENTAL
Intervention: Early introduction group (EIG) consuming 2.66 (1.85) g/wk of gluten from age 4 months.
Number of subjects: 1004
Study 32986087 — intervention group
Group type: COMPARATOR
Intervention: Standard introduction group (SIG) consuming 0.49 (1.40) g/wk of gluten between ages 4 and 6 months.
Number of subjects: 1004
Study 616026381 — intervention group
Group type: EXPERIMENTAL
Intervention: Bimatoprost-timolol fixed combination (BTFC)
Number of subjects: 39
Study 616026381 — intervention group
Group type: COMPARATOR
Intervention: Latanoprost
Number of subjects: 39
Study 36050727 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational intervention based on BASNEF model, 14 training sessions of 60 minutes each.
Number of subjects: 202
Study 36050727 — intervention group
Group type: COMPARATOR
Intervention: Control group (no educational intervention).
Number of subjects: 202
Study 36050727 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational intervention based on BASNEF model.
Number of subjects: 202
Study 36059199 — intervention group
Group type: EXPERIMENTAL
Intervention: Prenatal breast-feeding education on 'safe breastfeeding in the COVID-19 pandemic'
Number of subjects: 128
Study 36059199 — intervention group
Group type: COMPARATOR
Intervention: Standard care (control group)
Number of subjects: 128
Study 36059199 — intervention group
Group type: EXPERIMENTAL
Intervention: Prenatal breast-feeding education
Number of subjects: 128
Study 34617003 — intervention group
Group type: EXPERIMENTAL
Intervention: standard-dose CS
Number of subjects: 100
Study 34617003 — intervention group
Group type: EXPERIMENTAL
Intervention: standard-dose CS plus EEN (Modulen 1.5 kcal)
Number of subjects: 100
Study 34617003 — intervention group
Group type: EXPERIMENTAL
Intervention: short-course CS plus EEN
Number of subjects: 100
Study 34617003 — intervention group
Group type: COMPARATOR
Intervention: CS alone
Number of subjects: 100
Study 32545539 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention small group social networks (10 participants, 12 weekly sessions)
Number of subjects: 261
Study 34894034 — intervention group
Group type: EXPERIMENTAL
Intervention: Statins
Number of subjects: 0
Study 34894034 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 33362171 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-reported outcomes (PROs) questionnaire, filled before each visit
Number of subjects: 211
Study 33362171 — intervention group
Group type: COMPARATOR
Intervention: Usual visits (Control group A)
Number of subjects: 211
Study 93082162 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisone priming followed by alpha-interferon 2A
Number of subjects: 9
Study 36064745 — intervention group
Group type: EXPERIMENTAL
Intervention: LinkUP intervention (tailored education, motivational interviewing, and problem-solving strategies)
Number of subjects: 0
Study 36064745 — intervention group
Group type: COMPARATOR
Intervention: Didactic attention-control condition (information sharing only)
Number of subjects: 0
Study 34245666 — intervention group
Group type: EXPERIMENTAL
Intervention: Estetrol (E4) 15 mg and drospirenone (DRSP) 3 mg
Number of subjects: 1553
Study 34671976 — intervention group
Group type: EXPERIMENTAL
Intervention: Finger prick and look at blood
Number of subjects: 126
Study 34671976 — intervention group
Group type: COMPARATOR
Intervention: Finger prick and not look at blood
Number of subjects: 126
Study 34671976 — intervention group
Group type: COMPARATOR
Intervention: Sham finger prick
Number of subjects: 126
Study 36075994 — intervention group
Group type: EXPERIMENTAL
Intervention: S1 maintenance therapy (MT)
Number of subjects: 183
Study 36075994 — intervention group
Group type: COMPARATOR
Intervention: non-maintenance therapy (non-MT)
Number of subjects: 183
Study 35725414 — intervention group
Group type: EXPERIMENTAL
Intervention: Partial vertebrae body radiotherapy
Number of subjects: 66
Study 35725414 — intervention group
Group type: COMPARATOR
Intervention: Whole vertebrae body radiotherapy
Number of subjects: 66
Study 33596155 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise against a resistive load during repetitive short squeeze contractions
Number of subjects: 12
Study 33596155 — intervention group
Group type: COMPARATOR
Intervention: Exercise without a load during repetitive short squeeze contractions
Number of subjects: 12
Study 33596155 — intervention group
Group type: EXPERIMENTAL
Intervention: Long squeeze contraction against a load
Number of subjects: 12
Study 33596155 — intervention group
Group type: COMPARATOR
Intervention: Long squeeze contraction without a load
Number of subjects: 12
Study 32929634 — intervention group
Group type: EXPERIMENTAL
Intervention: Elderberry extract (15 ml orally twice a day for 5 days for ages 5-12; 15 ml 4 times a day for 5 days for > 12 years)
Number of subjects: 87
Study 32929634 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 87
Study 36242718 — intervention group
Group type: EXPERIMENTAL
Intervention: Deutetrabenazine (mean dose at week 8: 38.1 mg for Rollover; 36.5 mg for Switch)
Number of subjects: 119
Study 36242718 — intervention group
Group type: EXPERIMENTAL
Intervention: Deutetrabenazine (mean dose across cohorts after titration: 37.6 mg; final visit mean dose: 45.7 mg)
Number of subjects: 119
Study 32448712 — intervention group
Group type: COMPARATOR
Intervention: Moderate intensity exercise (EX)
Number of subjects: 413
Study 32448712 — intervention group
Group type: COMPARATOR
Intervention: Mindfulness-based stress reduction (MBSR)
Number of subjects: 413
Study 36125505 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant pembrolizumab
Number of subjects: 0
Study 36125505 — intervention group
Group type: COMPARATOR
Intervention: Placebo (KEYNOTE-564)
Number of subjects: 0
Study 36125505 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with pN1
Number of subjects: 0
Study 36125505 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients without LNI but with necrosis
Number of subjects: 0
Study 36125505 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients without LNI and necrosis
Number of subjects: 0
Study 34130688 — intervention group
Group type: EXPERIMENTAL
Intervention: Mistletoe extract (Abnoba Viscum Q®) administered subcutaneously during chemoradiotherapy.
Number of subjects: 52
Study 35094827 — intervention group
Group type: EXPERIMENTAL
Intervention: Solution-Oriented Therapy Programme (6 to 10 sessions)
Number of subjects: 0
Study 35094827 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention specified)
Number of subjects: 0
Study 33653361 — intervention group
Group type: EXPERIMENTAL
Intervention: Group training
Number of subjects: 81
Study 33653361 — intervention group
Group type: EXPERIMENTAL
Intervention: Training through booklet
Number of subjects: 81
Study 33653361 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 81
Study 35756985 — intervention group
Group type: EXPERIMENTAL
Intervention: Inspiratory Muscle Training (IMT)
Number of subjects: 20
Study 35756985 — intervention group
Group type: COMPARATOR
Intervention: Sham Inspiratory Muscle Training (sham-IMT)
Number of subjects: 20
Study 32717139 — intervention group
Group type: EXPERIMENTAL
Intervention: Genetically predicted serum IGF-1 levels
Number of subjects: 416
Study 34383607 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine (5 mg per kg of body mass)
Number of subjects: 11
Study 34383607 — intervention group
Group type: COMPARATOR
Intervention: Placebo (cellulose)
Number of subjects: 11
Study 33626213 — intervention group
Group type: EXPERIMENTAL
Intervention: Tacrolimus ointment (0.03%) application twice/day
Number of subjects: 20
Study 33626213 — intervention group
Group type: EXPERIMENTAL
Intervention: Microneedling once/week and tacrolimus ointment application directly after microneedling and twice/day the rest of the week
Number of subjects: 20
Study 33626213 — intervention group
Group type: EXPERIMENTAL
Intervention: Microneedling once/week alone
Number of subjects: 20
Study 33626213 — intervention group
Group type: EXPERIMENTAL
Intervention: Tacrolimus ointment application twice/day under occlusion by polyethylene foil
Number of subjects: 20
Study 32711546 — intervention group
Group type: EXPERIMENTAL
Intervention: Aggressive body temperature management (nasopharyngeal temperature 36.61 ± 0.18 °C)
Number of subjects: 70
Study 32711546 — intervention group
Group type: COMPARATOR
Intervention: Standard body temperature management (35.80 ± 0.18 °C)
Number of subjects: 70
Study 36416303 — intervention group
Group type: EXPERIMENTAL
Intervention: Group-Early Start Denver Model (G-ESDM) in inclusive classrooms
Number of subjects: 58
Study 36416303 — intervention group
Group type: COMPARATOR
Intervention: Group-Early Start Denver Model (G-ESDM) in specialised classrooms
Number of subjects: 58
Study 34265007 — intervention group
Group type: EXPERIMENTAL
Intervention: Lorcaserin 20 mg
Number of subjects: 22
Study 34265007 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study 32998940 — intervention group
Group type: EXPERIMENTAL
Intervention: LNG‐IUS
Number of subjects: 25
Study 616616941 — intervention group
Group type: EXPERIMENTAL
Intervention: Transition Preparation Training Program (TPT)
Number of subjects: 25
Study 616616941 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 25
Study 36409386 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief intervention
Number of subjects: 0
Study 36409386 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive intervention
Number of subjects: 0
Study 36409386 — intervention group
Group type: EXPERIMENTAL
Intervention: Any intervention arm
Number of subjects: 0
Study 36409386 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 34450192 — intervention group
Group type: EXPERIMENTAL
Intervention: REDUCE-IT eligible group
Number of subjects: 62464
Study 35195201 — intervention group
Group type: EXPERIMENTAL
Intervention: Chagas disease patients with undernutrition
Number of subjects: 131
Study 35195201 — intervention group
Group type: EXPERIMENTAL
Intervention: Chagas disease patients with hospital discharge
Number of subjects: 131
Study 35195201 — intervention group
Group type: COMPARATOR
Intervention: Control group (other etiologies)
Number of subjects: 131
Study 32804345 — intervention group
Group type: EXPERIMENTAL
Intervention: Cholecalciferol supplementation (500 UI/kg p.o. weekly)
Number of subjects: 30
Study 32804345 — intervention group
Group type: COMPARATOR
Intervention: Observation (− D)
Number of subjects: 30
Study 32688398 — intervention group
Group type: EXPERIMENTAL
Intervention: LIA with steroids (triamcinolone)
Number of subjects: 45
Study 32688398 — intervention group
Group type: COMPARATOR
Intervention: LIA without steroids
Number of subjects: 45
Study 32644829 — intervention group
Group type: EXPERIMENTAL
Intervention: Ischemic stroke patients (IS)
Number of subjects: 230
Study 32644829 — intervention group
Group type: COMPARATOR
Intervention: CYP2C19 metabolizers (intermediate and poor)
Number of subjects: 230
Study 32644829 — intervention group
Group type: COMPARATOR
Intervention: Control subjects
Number of subjects: 230
Study 35068454 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma L-carnitine
Number of subjects: 617
Study 35068454 — intervention group
Group type: EXPERIMENTAL
Intervention: L-carnitine addition to conventional risk factors
Number of subjects: 617
Study 35068454 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher L-carnitine and lower inflammatory status
Number of subjects: 617
Study 33188651 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopically assisted extracapsular dissection
Number of subjects: 50
Study 33188651 — intervention group
Group type: COMPARATOR
Intervention: Open parotidectomy
Number of subjects: 50
Study 35631283 — intervention group
Group type: EXPERIMENTAL
Intervention: Endobarrier insertion
Number of subjects: 47
Study 35631283 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifestyle modification with Endobarrier
Number of subjects: 47
Study 35631283 — intervention group
Group type: COMPARATOR
Intervention: Lifestyle modification without Endobarrier
Number of subjects: 47
Study 33236509 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 48
Study 35559855 — intervention group
Group type: EXPERIMENTAL
Intervention: Essential Coaching for Every Mother program (text messages related to newborn and maternal care for 6 weeks)
Number of subjects: 150
Study 35559855 — intervention group
Group type: EXPERIMENTAL
Intervention: Essential Coaching for Every Mother program (text messages)
Number of subjects: 150
Study 35559855 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard care)
Number of subjects: 150
Study 33248462 — intervention group
Group type: EXPERIMENTAL
Intervention: Automatic CRTd optimization (n=93)
Number of subjects: 191
Study 33248462 — intervention group
Group type: COMPARATOR
Intervention: Echocardiography‐guided CRTd optimization (n=98)
Number of subjects: 191
Study 35694945 — intervention group
Group type: EXPERIMENTAL
Intervention: Exoskeleton on, 'locking tendency' 0% (On_LT0)
Number of subjects: 22
Study 35694945 — intervention group
Group type: EXPERIMENTAL
Intervention: Exoskeleton on, 'locking tendency' 85% (On_LT85)
Number of subjects: 22
Study 35694945 — intervention group
Group type: COMPARATOR
Intervention: Exoskeleton off (Off)
Number of subjects: 22
Study 32306462 — intervention group
Group type: EXPERIMENTAL
Intervention: N-acetylcysteine, vitamin E, and vitamin C (NEC)
Number of subjects: 35
Study 32306462 — intervention group
Group type: COMPARATOR
Intervention: Sham
Number of subjects: 35
Study 33596854 — intervention group
Group type: EXPERIMENTAL
Intervention: Shared decision making (SDM) counseling session
Number of subjects: 78
Study 32237275 — intervention group
Group type: EXPERIMENTAL
Intervention: RAM cannula
Number of subjects: 90
Study 32237275 — intervention group
Group type: EXPERIMENTAL
Intervention: Hudson prongs
Number of subjects: 90
Study 32237275 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal mask
Number of subjects: 90
Study 34193434 — intervention group
Group type: EXPERIMENTAL
Intervention: Plan Well Guide (immediate intervention)
Number of subjects: 90
Study 34193434 — intervention group
Group type: COMPARATOR
Intervention: Delayed intervention (3-month wait period)
Number of subjects: 90
Study 32740320 — intervention group
Group type: EXPERIMENTAL
Intervention: Cuff pressure of 20 cmH2O (CP20)
Number of subjects: 184
Study 32740320 — intervention group
Group type: COMPARATOR
Intervention: Cuff pressure of 60 cmH2O (CP60)
Number of subjects: 184
Study 32740320 — intervention group
Group type: COMPARATOR
Intervention: Continuous positive airway pressure
Number of subjects: 184
Study 32740320 — intervention group
Group type: COMPARATOR
Intervention: Intermittent positive airway pressure
Number of subjects: 184
Study 32604288 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilateral regional maxillary nerve block (MNB) with 0.15 ml/kg of lidocaine clorhidrate 2% with epinephrine 1:50.000, under direct vision through the spheno palatine holes, before surgery.
Number of subjects: 60
Study 32604288 — intervention group
Group type: COMPARATOR
Intervention: Traditional general anesthesia plus local anesthesia (used in Hospital B).
Number of subjects: 60
Study 33601862 — intervention group
Group type: EXPERIMENTAL
Intervention: Stenosis group (28 patients)
Number of subjects: 88
Study 33601862 — intervention group
Group type: COMPARATOR
Intervention: Control group (60 patients)
Number of subjects: 88
Study 33813628 — intervention group
Group type: EXPERIMENTAL
Intervention: Septoplasty (SPL)
Number of subjects: 73
Study 33813628 — intervention group
Group type: EXPERIMENTAL
Intervention: Septorhinoplasty (SRP)
Number of subjects: 73
Study 36409508 — intervention group
Group type: EXPERIMENTAL
Intervention: VR distraction using a domed ceiling screen
Number of subjects: 88
Study 36409508 — intervention group
Group type: COMPARATOR
Intervention: Standard care (no VR)
Number of subjects: 88
Study 33588639 — intervention group
Group type: EXPERIMENTAL
Intervention: Living Well self-management intervention
Number of subjects: 15
Study 32053988 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent Calorie Restriction (ICR)
Number of subjects: 150
Study 32053988 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous Calorie Restriction (CCR)
Number of subjects: 150
Study 32053988 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 150
Study 32053988 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall weight loss
Number of subjects: 150
Study 616497285 — intervention group
Group type: EXPERIMENTAL
Intervention: High retention enema with Chaishao Chengqi decoction modified with salvia miltiorrhiza
Number of subjects: 83
Study 616497285 — intervention group
Group type: COMPARATOR
Intervention: Routine treatments (fasting, rehydration, acid suppression, inhibition of pancreatic enzyme activity, use of antibiotics)
Number of subjects: 83
Study 33731586 — intervention group
Group type: EXPERIMENTAL
Intervention: Hemoclips
Number of subjects: 298
Study 33731586 — intervention group
Group type: COMPARATOR
Intervention: APC
Number of subjects: 298
Study 33731586 — intervention group
Group type: EXPERIMENTAL
Intervention: Hemoclips monotherapy
Number of subjects: 298
Study 33731586 — intervention group
Group type: EXPERIMENTAL
Intervention: Hemoclips combination therapy
Number of subjects: 298
Study 33731586 — intervention group
Group type: EXPERIMENTAL
Intervention: Hemoclips combination therapy (in antithrombotic subgroup)
Number of subjects: 298
Study 33731586 — intervention group
Group type: EXPERIMENTAL
Intervention: Hemoclips combination therapy (after propensity score matching)
Number of subjects: 298
Study 34351478 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous thrombolysis with alteplase
Number of subjects: 0
Study 34351478 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 32348985 — intervention group
Group type: EXPERIMENTAL
Intervention: 1,000 mg IV ferric derisomaltose
Number of subjects: 54
Study 32348985 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 54
Study 35028890 — intervention group
Group type: EXPERIMENTAL
Intervention: High Dose Group (HDG) - 3750 IU VD3/day
Number of subjects: 248
Study 35028890 — intervention group
Group type: COMPARATOR
Intervention: Low Dose Group (LDG) - 600 IU VD3/day
Number of subjects: 248
Study 33406285 — intervention group
Group type: EXPERIMENTAL
Intervention: Return to formula low-energy-diet (LED)
Number of subjects: 123
Study 33406285 — intervention group
Group type: COMPARATOR
Intervention: No return to formula low-energy-diet (RT)
Number of subjects: 123
Study 33406285 — intervention group
Group type: EXPERIMENTAL
Intervention: Participants never recorded as having regained >2 kg or using RTs
Number of subjects: 123